Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
24.99 USD | +0.77% | -0.20% | -15.35% |
May. 10 | Morgan Stanley Adjusts Price Target on Mirum Pharmaceuticals to $53 From $57, Keeps Overweight Rating | MT |
May. 08 | Transcript : Mirum Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 08, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.35% | 1.18B | |
+29.77% | 49.46B | |
+1.00% | 42.58B | |
+49.51% | 42.49B | |
-5.26% | 29.09B | |
+13.68% | 26.61B | |
-22.99% | 18.64B | |
+8.22% | 13.16B | |
+32.41% | 12.55B | |
+24.01% | 12.1B |
- Stock Market
- Equities
- MIRM Stock
- News Mirum Pharmaceuticals, Inc.
- Earnings Flash (MIRM) MIRUM PHARMACEUTICALS Posts Q4 Revenue $69.6M, vs. Street Est of $67.9M